Johnson & Johnson (JNJ)
| Market Cap | 498.60B |
| Revenue (ttm) | 92.15B |
| Net Income (ttm) | 25.12B |
| Shares Out | 2.41B |
| EPS (ttm) | 10.35 |
| PE Ratio | 20.00 |
| Forward PE | 18.77 |
| Dividend | $5.20 (2.51%) |
| Ex-Dividend Date | Nov 25, 2025 |
| Volume | 4,083,667 |
| Open | 206.91 |
| Previous Close | 206.91 |
| Day's Range | 206.37 - 207.50 |
| 52-Week Range | 140.68 - 215.19 |
| Beta | 0.33 |
| Analysts | Buy |
| Price Target | 208.27 (+0.64%) |
| Earnings Date | Jan 21, 2026 |
About JNJ
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price target is $208.27, which is an increase of 0.64% from the latest price.
News
Best Dividend Aristocrats For January 2026
The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) underperformed SPY in 2025, gaining 7.2% versus SPY's 18.42%. Despite average underperformance, select Aristocrats like CAH (+74.18%), ALB (+66.90%...
The Big 3: JNJ, SNDK, TWLO
Healthcare, storage chips, and software adding AI integration take the focus of Tuesday's Big 3. Jenny Horne and Rick Ducat turn to technical analysis in Johnson & Johnson (JNJ), SanDisk (SNDK), and T...
Jim Cramer Says ‘The Year of Magical Investing' Is Over—Here's What To Do Now
CNBC's "Mad Money" host is waving the yellow flag.
More Upside For JNJ Stock In 2026?
Johnson & Johnson has just undergone its most significant transformation in decades. In 2023, the consumer health segment was spun off as Kenvue.
Dogs of the Dow Had a Strong Year as Dividends Paid Off
High-yielding Dow stocks outperformed the broader market this year. Will new Dow dogs Home Depot, Nike, and UnitedHealth keep the streak going?
Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”) today announced the successful completion of its acquisition of Halda Therapeutics OpCo, Inc. (“Halda”), a clinical-...
Best Dividend Kings: December 2025
Dividend Kings underperformed SPY in 2025, up 4.47% vs. SPY's 17.7%, but select Kings outperformed the index. Twenty-two Dividend Kings are identified as both potentially undervalued and offering long...
Johnson & Johnson halts mid-stage trial of experimental eczema drug
Johnson & Johnson said on Friday it has discontinued a mid-stage study of its experimental drug to treat patients with moderate to severe atopic dermatitis, after it failed to meet efficacy goals in a...
J&J ordered to pay record $1.5B in talc cancer lawsuit — while vowing to appeal ‘unconstitutional' ruling
The plaintiff's law firm said was the largest-ever sum awarded against J&J for a single plaintiff.
J&J vows appeal after US jury hits it with record $1.5 billion talc cancer award
A Baltimore jury ordered Johnson & Johnson and its subsidiaries to pay over $1.5 billion to a woman who claimed decades of exposure to asbestos in the company's talc-based products caused her peritone...
Over $1.5 Billion Baltimore Verdict Holds Johnson & Johnson Liable Over Iconic Baby Powder
BALTIMORE--(BUSINESS WIRE)--A Baltimore city jury has returned a verdict in favor of Cherie A. Craft, awarding her over $1.5 billion after finding that Johnson & Johnson and its subsidiaries exposed h...
Minnesota jury says Johnson & Johnson owes $65.5 million to woman with cancer who used talcum powder
A Minnesota jury awarded $65.5 million on Friday to a mother of three who claimed talcum products made by Johnson & Johnson exposed her to asbestos and contributed to her developing cancer in the lini...
Minnesota Jury Delivers $65.5 Million History-Making Verdict Against Johnson & Johnson
ST. PAUL, Minn.--(BUSINESS WIRE)--A Minnesota jury awarded $65.5 million to a 37-year-old mother of three minor children after finding in her favor in a lawsuit against Johnson & Johnson, concluding t...
Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma
- TRUFILL n-BCA is now indicated for embolization of the middle meningeal artery (MMA) for the treatment of symptomatic subacute and Chronic Subdural Hematoma (cSDH) as an adjunct to surgery. - Approv...
Johnson & Johnson: Valuation Premium Justified By Accelerating Growth And Mix Premiumization
Johnson & Johnson is rated a buy, with accelerating revenue and earnings growth driven by TREMFYA, CARVYKTI, and robust MedTech innovation. JNJ's portfolio reshaping (divesting Orthopaedics and focusi...
U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)
RYBREVANT FASPRO™, the first and only subcutaneous therapy for patients with EGFR-mutated NSCLC, reduces administration time from hours to minutes and significantly reduces administration-related reac...
Final Trade: JNJ, NVO, UBER, BMY
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, January 21st to review fourth-quarter results. J...
US FDA grants priority voucher to J&J's blood cancer treatment
The U.S. Food and Drug Administration said on Monday it has granted a national priority voucher to Johnson & Johnson's treatment for a type of blood cancer, bringing the total number of products recei...
California Jury Awards $40 Million in Landmark Talc Verdict Against Johnson & Johnson
LOS ANGELES--(BUSINESS WIRE)--A Los Angeles Superior Court jury on Friday delivered a $40 million verdict against Johnson & Johnson. The trial involved two women who developed ovarian cancer after dec...
Jury orders Johnson & Johnson to pay $40 million to two women in latest talc trial
A California jury on Friday awarded $40 million to two women who said Johnson & Johnson's baby powder was to blame for their ovarian cancer.
U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
Expanded indication for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) plus prednisone marks the first FDA-approved precision medicine combination treatment for patients with BRCA2-mut...
Johnson & Johnson: Reliable Cash Flows, Moderate Expectations
Johnson & Johnson has surged 14% since my last update, surpassing my $188 target, and now trades near $200. Top-line growth is accelerating, but revenue expansion remains below industry rates and is p...
GS Equity Income Fund: Q3 2025 Witnesses Fundamental Strength And Expansive Margin Opportunities
The US Equity Income Fund underperformed its benchmark, the Russell 1000 Value Index, net of fees during the third quarter. Enterprise software company, Oracle Corporation, was a top contributor to re...
5 defensive stocks traders are buying before the Fed rate-cut decision
With the Federal Reserve set to announce its final policy decision of 2025 on Wednesday, investors are rotating into defensive positions. More than the rate-cut possibility (which is around 90% as per...